The Largest-Ever Fibromyalgia Study Just Found a Gut-Brain Connection

If you live with fibromyalgia, the condition that causes widespread muscle and joint pain, fatigue, and tenderness across the body, you have probably heard it dismissed as "all in your head," or wondered yourself whether something happening in your gut is quietly feeding the pain. A new study, the largest genetic analysis of fibromyalgia ever conducted, does not settle that question outright, but it draws the sharpest genetic map of the disease so far, and one of its most intriguing side findings points toward the gut-brain axis (the two-way signaling network linking digestive function to the brain and nervous system).

Key takeaways

• Researchers analyzed genetic data from 2.5 million people (including 54,629 with fibromyalgia) and identified 26 genome-wide-significant risk regions, published in Nature Medicine.
• Fibromyalgia shares strong genetic overlap (correlation above 0.7) with low back pain, PTSD, and irritable bowel syndrome (IBS), genes active in enteric neurons (nerve cells controlling gut movement and sensation) were significantly enriched among the risk genes, pointing to a shared gut-brain mechanism.
• The genetic risk score built from this data only modestly predicts who develops fibromyalgia (AUC of 0.59, where 0.5 is chance and 1.0 is perfect), and the sample is roughly 90% European-ancestry, so it is not a diagnostic tool yet and does not generalize evenly.
• This is an association study: it flags genetic risk factors, not proof that any single gene or gut pathway causes fibromyalgia.

Study Pinpoints 26 Genetic Risk Regions for Fibromyalgia

A team of more than 50 researchers across seven countries analyzed genetic data from 2,563,755 people, 54,629 with a fibromyalgia diagnosis and just over 2.5 million without, pooled across 11 cohorts from the US, UK, Finland, Estonia, Denmark, and Iceland, according to the study, published in Nature Medicine and reported by Fred Hutchinson Cancer Center, whose researchers co-led the work. This kind of study is called a genome-wide association study, or GWAS (a scan comparing millions of genetic markers between people with and without a condition to find which ones show up more often in cases). The analysis turned up 26 independent genome-wide-significant risk loci, specific spots in the genome where a genetic variant is statistically linked to fibromyalgia risk. The strongest signal sat in the HTT gene (best known for its role in Huntington's disease), where one variant raised the odds of fibromyalgia by about 9% (odds ratio 1.09). "For decades, patients have been dismissed or told their pain is simply psychological," one of the study's co-senior authors said in the Fred Hutch statement. "Our findings confirm the condition has a clear biological basis."

Why Fibromyalgia Often Travels With IBS, Back Pain, and PTSD

Anyone with fibromyalgia who also deals with digestive trouble, chronic back pain, or PTSD may not find this surprising: the study found genetic correlations above 0.7 between fibromyalgia and each of low back pain, PTSD, and IBS, a statistical measure showing that a large share of the same genetic variants raising fibromyalgia risk also raise risk for these other conditions. That mirrors what clinicians have long observed. Research on the fibromyalgia-IBS overlap has previously pointed to shared gut-brain signaling as a likely explanation, and this GWAS adds a genetic layer to that picture. Fibromyalgia itself is diagnosed roughly three times more often in women than men, about 6.4% of US adults live with fibromyalgia overall, according to the NIH's clinical overview, broken down as roughly 7.7% of women and 4.9% of men, though the study found no evidence of genetic differences by sex, so the gap likely reflects a mix of biology, diagnostic bias, and reporting differences that genetics alone can't explain.

How Scientists Analyzed Genetic Data From 2.5 Million People

What makes this study more convincing than earlier, smaller fibromyalgia genetics work is scale and consistency: pooling 2.5 million genomes across 11 independent cohorts is large enough to detect gene-by-gene effects that are individually tiny (most raise risk by single-digit percentages) but statistically solid, and seeing the same signals recur across separately collected cohorts strengthens confidence they are real rather than noise. The tradeoff is that a GWAS of this kind can only show which genetic variants are statistically associated with a diagnosis, not what any given gene actually does in the body to cause pain, which is why the researchers followed up with a separate analysis of which cell types and tissues the risk genes are most active in.

What the Gut-Brain Signal Means for People With Fibromyalgia

That follow-up analysis is where the gut connection surfaces: risk genes for fibromyalgia were significantly enriched (concentrated well beyond chance, at P=7.9×10^-6) in enteric neurons, the network of nerve cells lining the gut that governs digestive motility and sensation, sometimes called the "second brain." Combined with the strong genetic overlap with IBS, this suggests part of fibromyalgia's biology may run through the same nerve circuitry that regulates the gut, not just the central nervous system. For someone with fibromyalgia and persistent GI symptoms, that is a reason to bring both up with a doctor as possibly connected rather than coincidental, and to expect research attention on gut-nervous-system pathways going forward. It is not, however, evidence that any specific diet, probiotic, or gut-targeted supplement improves fibromyalgia symptoms, the study did not test any intervention at all.

The Study's Limitations: What It Doesn't Prove

Three caveats matter here. First, this is a GWAS association, not proof of a causal mechanism, the enteric-neuron finding is a secondary enrichment result, not the study's central claim. Second, the cohort is about 90% European-ancestry, so how well these risk loci and their gut-brain implications hold up in other ancestries is genuinely unknown. Third, the polygenic risk score built from all 26-plus loci together only reached an AUC of 0.59 in European-ancestry participants, barely better than a coin flip's 0.5, meaning this genetic profile is nowhere close to useful for predicting or diagnosing fibromyalgia in an individual person today.

What Comes Next in Fibromyalgia Research

The HTT signal points toward a receptor called GPR52, which drug developers have already been targeting for Huntington's disease, giving researchers an existing pharmacological lead to test in fibromyalgia rather than starting from zero. The study's authors have also launched a Chronic Pain Genomics Consortium to extend this kind of large-scale genetic mapping to other pain conditions. Expect follow-up work to test whether the enteric-neuron and IBS genetic overlap holds up in more diverse cohorts, and whether it translates into anything clinically actionable, that timeline is not yet public.

Common Questions

Does this mean fibromyalgia is caused by gut bacteria? No. The study looked at genetic variants and where the genes they sit near are active (including gut nerve cells), not at gut microbiome composition. It suggests a nervous-system pathway connecting gut and pain signaling, not a microbiome cause.

Can this genetic test diagnose fibromyalgia? No. The polygenic score built from this study's findings has an AUC of just 0.59 (near chance), far too weak for individual diagnosis or prediction.

Why do fibromyalgia and IBS overlap so often? This study found their genetic risk factors overlap by more than 0.7 (on a 0 to 1 scale), and genes tied to fibromyalgia risk are unusually active in the nerve cells that regulate gut function, suggesting shared biology rather than coincidence.

Does this study apply to everyone with fibromyalgia? Not equally. About 90% of participants were of European ancestry, so the specific risk variants identified may not generalize to other populations, and more diverse research is needed.

References

1. (2026). The genetic architecture of fibromyalgia across 2.5 million individuals. Nature Medicine. https://doi.org/10.1038/s41591-026-04492-6